Sema is a GLP-1 receptor agonist analogue of human glucagon-like peptide-1, engineered with a C18 fatty diacid side chain for albumin binding and extended half-life, studied in metabolic and receptor pharmacology research
With medications like Wegovy and Saxenda that are specifically approved for weight loss, and others like Ozempic and Trulicity that have shown positive results in managing blood sugar levels and concurrent weight reduction, a robust implementation of GLP-1 drugs could pave the way for a notable reduction in obesity and diabetes-related complications
The Lancet, 368 (9548), 1696-1705
Beyond objective clinical outcomes, GI motility disturbances can substantially affect patient-reported outcomes, including daily functioning, dietary intake, and overall quality of life
The semaglutide dosage calculator helps you dial in your medication amounts, but your protein calculator is equally important for outcomes